Provider treatment intensity and outcomes for patients with early-stage bladder cancer. - Wikidata - wikimedia - TriplyDB

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

http://www.wikidata.org/entity/Q37158594

about

Population based trends in the surgical treatment of benign prostatic hyperplasia.Patterns of care for early stage bladder cancer.The health economics of bladder cancer: an updated review of the published literature.The crossroads of evidence-based medicine and health policy: implications for urology.Quality of care in patients with bladder cancer: a case report?Hospital-level variation in the quality of urologic cancer surgery.Variation in hospital treatment patterns for metastatic colorectal cancer.Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]Does uneven geographic distribution of urologists affect bladder and prostate cancers mortality? national health insurance data in korea from 2007 to 2011.The Role of Population-Based Observational Research in Bladder Cancer The association of regional intensity of neurosurgical care with spinal fusion surgery in the USA.Managing muscle-invasive bladder cancer in the elderly.Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.Challenges in non-muscle invasive bladder cancer: lessons from a regional review.Improving bladder cancer patient care: a pharmacoeconomic perspective.Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care.Assembling and validating data from multiple sources to study care for Veterans with bladder cancer.Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.Contemplating bladder cancer care: can we cut costs and improve quality of care?The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.Bladder cancer: utility of MRI in detection of occult muscle-invasive disease.Challenges facing regionalization of radical cystectomy.The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera Extent of Risk-Aligned Surveillance for Cancer Recurrence Among Patients With Early-Stage Bladder Cancer

P2860

Q31100390-9FD9774F-D519-4DB3-B15E-DAFE448BE788 Q33875940-1397F62F-BCED-45B8-9C2D-3C963E18ADFA Q34430559-744ECEDA-C54C-466B-89F1-AAC4268FDACF Q34996363-CE94706B-47E0-4EB5-B702-91DFE66CDEA5 Q35541862-00BCC4DC-6B71-4D17-9B37-9B1FE8E3A9C2 Q35740209-E222FAF4-D303-4866-A4AE-D43A134E3FAD Q36117240-F87C3D05-923E-43AF-BCF3-9583C0CEFBC4 Q36236479-6814449B-3ECD-4CD9-8F39-3D56A2F1EF01 Q36394910-452B3B69-8C25-4B7B-A2B2-5A05D0DC8D90 Q37053750-30B85E5C-8C68-4613-942F-6D8B51119AF6 Q37650033-BE5638E8-2518-43AB-A2BF-BC55FD99B47B Q37765589-8E5324B9-D835-4D97-B36E-05DFE167369C Q37813081-42800BFB-14DC-4B78-B364-297AC3CD0D8C Q38002986-5DA6AC90-476E-4EDE-BE4D-8405C976E758 Q38114945-CE15F05D-B165-4CF7-9B8D-DB238BBBEEB4 Q40306356-89B73AAA-D59B-440E-A78E-8783805BE3BE Q41624975-38ABB934-3921-41E0-9701-0203316F9749 Q42580837-BB0F4DE3-2A03-4406-8857-74C77347D897 Q45007456-99761F91-1078-4C26-90FA-BE6F0E921FC3 Q46780630-E61F4E97-74A1-44EE-85DF-4AB988505330 Q47927919-F62611BF-5474-4286-96E3-BE7C6CFE112C Q52625811-ECCC9254-847F-4A1F-A239-8F82133E48DB Q54960847-417790E9-F3AE-4F9C-9594-6DFB513E1057 Q57795877-22E8848F-E903-47A8-B803-C4B58F09FB9C Q59136607-7DABCF32-3AAE-4A54-B9D6-A7334C2166F9

P2860

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

http://www.wikidata.org/entity/Q37158594

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@en

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@nl

type

label

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@en

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@nl

prefLabel

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@en

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@nl

P1433

Q37158594-0C82D5BF-B27C-4760-9C10-33567E6FBE2A

P1476

Q37158594-0FD74CE8-7E75-4266-9309-6871FEE587CC

P2093

Q37158594-38487430-B26F-4433-A2FD-9A32FCFEC419

Q37158594-615993EC-F1FE-4307-9BC9-C1724143BBC5

Q37158594-86E782FB-462B-4B7B-AA90-B213C609495B

Q37158594-B5603158-6B4B-4428-80C5-9950C1790B5D

Q37158594-F2E6FDE0-DD61-4239-8F2A-4B825B1FC870

P2860

Q37158594-13C1D38D-6FEB-41FA-99B3-347FB6928DCB

Q37158594-150DBC46-22A9-4955-BB1C-49F9A666D355

Q37158594-2214BEFD-ED9B-488C-95F7-ADCD8376A9F9

Q37158594-351940B8-44DA-4CF9-A573-A1F69F345120

Q37158594-3A6748E7-C891-4FE7-96E1-6F7043B46263

Q37158594-3EA18BD1-77BF-4C34-B767-42C0EFFFB508

Q37158594-40F44C74-BD1A-4ADA-98FE-723EEBE137F9

Q37158594-69103184-DB2A-4989-9684-BC547B605CB0

Q37158594-8CDD03EE-6431-4152-B14C-ACC61A2225A9

Q37158594-9BA850B7-FED7-4316-829B-45F347A449C7

P304

Q37158594-A9942838-41D8-4B30-8820-5B7CCC8A1450

P31

Q37158594-D6B6702D-74EC-4695-B205-007D30C93E15

P356

Q37158594-15E276D4-603E-4C2A-AA61-E17050976DBD

P407

Q37158594-9D4048A6-B9CC-4ED8-B881-894D8735B2C0

P433

Q37158594-2E9A8CDB-B043-40C5-B3E4-B7DD35B17665

P478

Q37158594-1744E9F9-BD5A-4A38-862A-343025ADA5A0

P577

Q37158594-7ECB7AA6-EAA3-42D0-A7A5-05E6B7BC0F5D

P5875

Q37158594-54A46DDE-0CB9-4A5B-A8F8-839697FEDA8B

P698

Q37158594-996C53D8-679A-4A0F-8D9D-FC652CAAD31C

P932

Q37158594-A9B16A21-D02A-4BA8-88CE-11F9E20C686B

P356

P1433

Journal of the National Cancer Institute

P1476

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

@en

P2093

Brent K Hollenbeck

http://www.w3.org/2001/XMLSchema#string

James E Montie

http://www.w3.org/2001/XMLSchema#string

John D Birkmeyer

http://www.w3.org/2001/XMLSchema#string

Rodney L Dunn

http://www.w3.org/2001/XMLSchema#string

Zaojun Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Development of a comorbidity index using physician claims data.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Estimating health care costs related to cancer treatment from SEER-Medicare data.

Indications for early cystectomy.

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations.

Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods

Cox regression analysis of multivariate failure time data: the marginal approach.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

P304

571-580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJP039

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24262861

http://www.w3.org/2001/XMLSchema#string

P698

19351919

http://www.w3.org/2001/XMLSchema#string

P932

2669100

http://www.w3.org/2001/XMLSchema#string